Methylphenidate
| Evidence Level: L2 | Predicted Indications: 4 |
Table of Contents
Methylphenidate: From ADHD to Specific Developmental Disorder
Note on candidate selection: This evidence pack contains four TxGNN-predicted indications for methylphenidate. The single highest-scoring prediction (faciodigitogenital syndrome, 99.998%) currently has no supporting clinical trial or literature evidence and its scoring/rationale fields remain unprocessed (“pending”). Chondromyxoid fibroma (rank 2) has been formally assessed and returned a Hold with no plausible mechanistic link. This report therefore focuses on the candidate with the strongest completed evidence review — specific developmental disorder (rank 3, evidence level L2) — as the most clinically meaningful basis for evaluation.
One-Sentence Summary
Methylphenidate is a dopamine/noradrenaline reuptake inhibitor whose established clinical use (evident throughout the trial and literature context in this evidence pack) is Attention-Deficit/Hyperactivity Disorder (ADHD). The TxGNN model predicts it may also be effective for Specific Developmental Disorder, with 1 completed Phase 2 RCT directly on point and 15 supporting/contextual trials currently identified, though no dedicated literature (PubMed) evidence has yet been retrieved.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in the UK regulatory data within this evidence pack (drug not currently marketed in the UK); established international use is ADHD, referenced throughout the supporting trial evidence |
| Predicted New Indication | Specific developmental disorder |
| TxGNN Prediction Score | 99.99% (score 0.9998779) |
| Evidence Level | L2 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed original mechanism-of-action data is flagged as a data gap (DG002) in this evidence pack. However, the repurposing rationale supplied alongside the prediction confirms that methylphenidate acts as a dopamine/noradrenaline reuptake inhibitor, enhancing prefrontal cortical executive function and attentional regulation — the same mechanism underlying its established use in ADHD.
“Specific developmental disorder” is a broad diagnostic category that includes conditions such as childhood apraxia of speech and other neurodevelopmental/motor-coordination disorders. These conditions frequently overlap with executive-function and neuromotor-coordination deficits, which is the biological rationale for extending methylphenidate beyond ADHD. Several trials in the evidence base (e.g. in 22q11.2 deletion syndrome and autism spectrum disorder) further support a mechanistic bridge between dopaminergic modulation and neurodevelopmental symptom domains.
Importantly, specific developmental disorder is a distinct diagnostic entity from ADHD, and the current evidence — while including one directly relevant completed RCT — remains preliminary. The mechanistic plausibility is reasonable, but confirmatory, adequately powered trials specific to this diagnostic category are still needed.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT05185583 | Phase 2 | Completed | 18 | Double-blind, randomised, placebo-controlled crossover trial testing methylphenidate for speech intelligibility in children with childhood apraxia of speech (a specific developmental disorder subtype). Directly relevant, Grade A. |
| NCT04647500 | N/A | Completed | 45 | Methylphenidate’s modulation of the dopaminergic system on memory and executive processes in individuals with 22q11.2 deletion syndrome. Grade B. |
| NCT02167048 | Phase 1/2 | Active, not recruiting | 52 | Double-blind crossover comparing low- vs normal-dose psychostimulants on executive function in children with ADHD (combined/inattentive type). Grade B. |
| NCT05974241 | Phase 4 | Completed | 36 | Crossover trial of methylphenidate vs aripiprazole for irritability in children with ADHD and emotion dysregulation. Grade B. |
| NCT01470261 | N/A | Completed | 1398 | ADDUCE project: large observational study of methylphenidate’s chronic effects on growth, neurological, psychiatric and cardiovascular systems. Grade B. |
| NCT07024303 | Early Phase 1 | Not yet recruiting | 20 | Comparing medication and behavioural treatment for challenging behaviour in children/adolescents with autism. Grade B. |
| NCT01363544 | Phase 2/3 | Completed | 112 | Exercise and neurofeedback intervention combined with pharmacological treatment (methylphenidate) for ADHD, described as a developmental disorder. |
| NCT05916339 | Phase 4 | Recruiting | 500 | Pragmatic SMART-design trial comparing methylphenidate and amphetamine for ADHD in children/youth with autism spectrum disorder. |
| NCT00310986 | N/A | Unknown | 22 | RCT of breathing meditation combined with methylphenidate for children with ADHD. |
| NCT01554046 | N/A | Completed | 40 | Familial response to methylphenidate (Ritalin IR) in ADHD — symptom improvement and side-effects. |
Literature Evidence
Currently no related literature (PubMed) has been retrieved for this specific indication.
UK Market Information
No UK marketing authorisation is currently held for methylphenidate under this evidence pack (market_status: Not marketed; total_licenses: 0). Methylphenidate is, however, a long-established stimulant class medicine internationally (BNF: CNS stimulants and drugs used for ADHD); UK-specific licence data should be verified directly against the MHRA product database before any regulatory decision is made.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: this evidence pack flags two outstanding data gaps relevant to safety review — MHRA/SmPC warnings and contraindications (blocking, DG001) and detailed mechanism-of-action data (high priority, DG002). Neither is yet available and should be resolved before any safety-sensitive decision.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: One completed, directly relevant Phase 2 RCT (n=18) shows methylphenidate has been formally tested in a specific developmental disorder subtype (childhood apraxia of speech), supported by a plausible dopaminergic mechanism and a body of contextual trials in overlapping neurodevelopmental populations. However, the evidence base is still limited to a single small trial and heterogeneous, indirectly related studies, so this should be treated as a research-stage signal rather than a ready-to-implement indication.
To proceed, the following is needed:
- Larger, adequately powered confirmatory RCTs specifically defining and testing “specific developmental disorder” as the primary endpoint
- Resolution of blocking data gap DG001 (MHRA/SmPC warnings and contraindications)
- Resolution of high-priority data gap DG002 (detailed mechanism-of-action data)
- Confirmation of UK marketing authorisation and licence status, as none is currently on record
- Re-evaluation of the top TxGNN-scored candidate (faciodigitogenital syndrome) once clinical trial and literature evidence become available, and continued monitoring of dysthymic disorder (L4, currently literature-only, mechanistically plausible via psychostimulant antidepressant augmentation)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.